Ashkan H Rad (Ashkan Hassankhani Rad)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 11

Top Topics

Radical Prostatectomy

Prostate Cancer

Low Density Lipoprotein

Oxide Nanoparticles

Top Venues

Molecules (Basel, Switzerland)

BioImpacts : BI

This page only lists publications with an associated author ORCID identifier.

Publications

Oliver C McGehee, Hassan Y Ebrahim, Ashkan H Rad, Khaldoun S Abdelwahed, Ethar A Mudhish, Judy A King, Iman E Helal, Sharon A Meyer, Khalid A El Sayed
Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice. Molecules (Basel, Switzerland) 28 (3) (2023)
Khaldoun S Abdelwahed, Abu Bakar Siddique, Hassan Y Ebrahim, Mohammed H Qusa, Ethar A Mudhish, Ashkan H Rad, Mourad Zerfaoui, Zakaria Y Abd Elmageed, Khalid A El Sayed
Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Marine drugs 21 (4) (2023)
Khaldoun S Abdelwahed, Abu Bakar Siddique, Hassan Y Ebrahim, Mohammed H Qusa, Ethar A Mudhish, Ashkan H Rad, Mourad Zerfaoui, Zakaria Y Abd Elmageed, Khalid A El Sayed
Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Marine drugs 21 (4) (2023)
Oliver C McGehee, Hassan Y Ebrahim, Ashkan H Rad, Khaldoun S Abdelwahed, Ethar A Mudhish, Judy A King, Iman E Helal, Sharon A Meyer, Khalid A El Sayed
Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice. Molecules (Basel, Switzerland) 28 (3) (2023)
Khaldoun S Abdelwahed, Abu Bakar Siddique, Hassan Y Ebrahim, Mohammed H Qusa, Ethar A Mudhish, Ashkan H Rad, Mourad Zerfaoui, Zakaria Y Abd Elmageed, Khalid A El Sayed
Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Marine drugs 21 (4) (2023)
Oliver C McGehee, Hassan Y Ebrahim, Ashkan H Rad, Khaldoun S Abdelwahed, Ethar A Mudhish, Judy A King, Iman E Helal, Sharon A Meyer, Khalid A El Sayed
Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice. Molecules (Basel, Switzerland) 28 (3) (2023)
Oliver C McGehee, Hassan Y Ebrahim, Ashkan H Rad, Khaldoun S Abdelwahed, Ethar A Mudhish, Judy A King, Iman E Helal, Sharon A Meyer, Khalid A El Sayed
Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice. Molecules (Basel, Switzerland) 28 (3) (2023)
Oliver C McGehee, Hassan Y Ebrahim, Ashkan H Rad, Khaldoun S Abdelwahed, Ethar A Mudhish, Judy A King, Iman E Helal, Sharon A Meyer, Khalid A El Sayed
Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice. Molecules (Basel, Switzerland) 28 (3) (2023)
Khaldoun S Abdelwahed, Abu Bakar Siddique, Hassan Y Ebrahim, Mohammed H Qusa, Ethar A Mudhish, Ashkan H Rad, Mourad Zerfaoui, Zakaria Y Abd Elmageed, Khalid A El Sayed
Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. Marine drugs 21 (4) (2023)
Oliver C McGehee, Hassan Y Ebrahim, Ashkan H Rad, Khaldoun S Abdelwahed, Ethar A Mudhish, Judy A King, Iman E Helal, Sharon A Meyer, Khalid A El Sayed
Towards Developing Novel Prostate Cancer Recurrence Suppressors: Acute Toxicity of Pseurotin A, an Orally Active PCSK9 Axis-Targeting Small-Molecule in Swiss Albino Mice. Molecules (Basel, Switzerland) 28 (3) (2023)
Ashkan H Rad, Farshid Asiaee, Sevda Jafari, Ali Shayanfar, Afsaneh Lavasanifar, Ommoleila Molavi
Poly(ethylene glycol)-poly(ε-caprolactone)-based micelles for solubilization and tumor-targeted delivery of silibinin. BioImpacts : BI 10 (2) (2019)